MitochondrialModerate Evidence

SS-31

Also known as: Elamipretide, Bendavia, MTP-131

Mitochondria-targeted peptide (elamipretide). FDA granted it accelerated approval in September 2025 as Forzinity for Barth syndrome, a rare inherited disease.

Evidence

Moderate

FDA status

FDA-approved

Source

Synthetic mitochondria-targeted peptide

Overview

Mitochondria-targeted peptide (elamipretide). FDA granted it accelerated approval in September 2025 as Forzinity for Barth syndrome, a rare inherited disease.

Mechanism of Action

Selectively binds cardiolipin on inner mitochondrial membrane, stabilizes electron transport chain complexes, restores ATP production efficiency, reduces oxidative stress and ROS, eliminates dysfunctional mitochondria while preserving healthy ones, restores redox balance.

What research has looked at

Effects reported in studies, not proven benefits. See the evidence section below for how strong the research is.

  • Mitochondrial energy production
  • Reduces oxidative damage
  • Muscle strength in Barth syndrome
  • Age-related mitochondrial decline (research)
  • Heart failure (trials)
  • Eye and nerve disease (trials)

Researched for

Includes FDA-approved uses where marked; other items are research topics, not approved uses.

Mitochondrial disordersHeart failureAge-related energy declineNeurodegenerative diseasesIschemia-reperfusion injuryBarth syndrome (FDA-approved use)

How Gabriel approaches peptides

Through Gabriel, licensed clinicians may prescribe BPC-157, TB-500, MOTS-c, epitalon and semax (nasal) as compounded medications from licensed 503A pharmacies, under HHS's October 28, 2026 interim policy, and only when appropriate. They are not FDA-approved, and Gabriel never gives peptide dosing. SS-31 isn't prescribed through Gabriel. If you're thinking about it, Gabriel can help you find a licensed clinician to look at the cause of what you're dealing with and the options with stronger evidence.

Read the peptide therapy guide

Research & Evidence

Evidence Level
Moderate
Studies

Clinical trials including TAZPOWER in Barth syndrome

Summary

FDA granted accelerated approval for Barth syndrome (patients at least 30 kg) in September 2025, based on improved knee-extension muscle strength. FDA requires a further trial to confirm benefit. Trials in heart failure and other mitochondrial diseases have had mixed results.

Safety Information

Potential Side Effects

  • •Injection site reactions
  • •Headache

Contraindications

  • Pregnancy
  • Breastfeeding

Interactions

  • ⚠None well-documented

Quick Facts

CategoryMitochondrial
SourceSynthetic mitochondria-targeted peptide
StatusFDA-approved (accelerated approval, September 2025) as Forzinity for Barth syndrome; other uses are investigational